Skip to main content Skip to section navigation Skip to footer
Careers Search
Grace Therapeutics, Inc. Homepage
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • GTx-104
    • Overview
    • STRIVE-ON Trial
    • Publications
  • Our Pipeline
  • Newsroom
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEC Filings
    • Governance
  • Contact Us
  • Careers
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events
    • Email Alerts
  • Company Info
    • Company Profile
    • Presentations
    • Contacts
    • FAQ
  • Financial Results
  • Stock Data
    • Quote and Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Section 16 Filings
    • Tax Notifications
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events
  • Email Alerts
Apr 1, 2019 9:20 am EDT
Acasti Pharma Announces Publication of CaPre Bioavailability Study in Leading Peer-Reviewed Journal
Mar 26, 2019 8:30 am EDT
Acasti Pharma to Present at the 2019 Spring Investor Summit in New York City on April 2nd
Mar 13, 2019 8:30 am EDT
Acasti Pharma to Present at the Oppenheimer 29th Annual Healthcare Conference on March 19th
Feb 21, 2019 9:15 am EST
Acasti Pharma Recognized in TSX Venture Exchange’s 2019 Venture 50
Feb 14, 2019 8:05 am EST
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Feb 8, 2019 8:00 am EST
Acasti Pharma Schedules Third Quarter Fiscal 2019 Conference Call
Jan 9, 2019 8:00 am EST
Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
Dec 31, 2018 8:00 am EST
Acasti Pharma Announces TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia Has Now Exceeded 65% Randomization, and More Than 100 Patients (>20%) Have Completed Their 6 Month Treatment Plan
Dec 20, 2018 8:00 am EST
Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
Nov 14, 2018 8:00 am EST
Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • …
  • Page 29
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
  • account_treeSitemap
©2025 Grace Therapeutics, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement
  • Manage Cookie Preferences